RDS发病的主要原因是早产儿肺发育不成熟,不能产生足够的肺表面活性物质(Pulmonary Surfactant,PS),控制表面活性蛋白合成的基因缺陷是影响RDS发病的遗传机制。
基于4个网页-相关网页
上述改变幅度与喷注的肺表面活性物质的剂量正相关。
And the extents of above changes were positively correlated with dosing of the insufflated lung surfactant.
目的探讨肺表面活性物质治疗新生儿胎粪吸入综合征的有效性及临床价值。
Objective To study the efficacy of pulmonary surfactant in newborn infants with meconium aspiration syndrome.
目的探讨肺表面活性物质（PS）与机械通气联用治疗新生儿肺透明膜病（HMD）的疗效及临床价值。
Objective To explore the effect of pulmonary surfactant (PS) combined with mechanical ventilation on pulmonary hyaline membrane disease of newborn (HMD) in newborn.
应用推荐